Clinical Trial Update: BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing BIBF 1120 (nintedanib) to bevacizumab in metastatic colorectal cancer has completed, with results posted in February 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04